Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Plasma cell myeloma refractory? 489 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 489 reports of Plasma cell myeloma refractory have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.1% of all adverse event reports for LENALIDOMIDE.

489
Reports of Plasma cell myeloma refractory with LENALIDOMIDE
0.1%
of all LENALIDOMIDE reports
64
Deaths
45
Hospitalizations

How Dangerous Is Plasma cell myeloma refractory From LENALIDOMIDE?

Of the 489 reports, 64 (13.1%) resulted in death, 45 (9.2%) required hospitalization, and 16 (3.3%) were considered life-threatening.

Is Plasma cell myeloma refractory Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 489 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Plasma cell myeloma refractory?

BORTEZOMIB (618) DEXAMETHASONE (513) DARATUMUMAB (404) CARFILZOMIB (386) POMALIDOMIDE (280) CYCLOPHOSPHAMIDE (237) IXAZOMIB (132) DOXORUBICIN (115) ETOPOSIDE (90) THALIDOMIDE (89)

Which LENALIDOMIDE Alternatives Have Lower Plasma cell myeloma refractory Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Plasma cell myeloma refractory Reports All Drugs Causing Plasma cell myeloma refractory LENALIDOMIDE Demographics